4.4 Article

Migraine prevalence by age and sex in the United States: A life-span study

Journal

CEPHALALGIA
Volume 30, Issue 9, Pages 1065-1072

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/0333102409355601

Keywords

migraine; menstrual migraine; headache; epidemiology; menstruation; paediatric headache

Funding

  1. Endo Pharmaceuticals Inc., Chadds Ford, Pennsylvania, USA
  2. Advanced Bionics
  3. Allergan Pharmaceuticals
  4. AstraZeneca
  5. Boehringer-Ingelheim
  6. Bristol-Myers Squibb
  7. Cierra
  8. Endo Pharmaceuticals Inc.
  9. GlaxoSmithKline
  10. Minster
  11. Merck Co., Inc.
  12. Neuralieve
  13. Novartis
  14. OrthoMcNeil Neurologics Inc.
  15. Pfizer Inc
  16. Pozen Inc.
  17. ProEthics, Ltd
  18. St Jude Children's Research Hospital

Ask authors/readers for more resources

The present study assessed age-and sex-specific patterns of migraine prevalence in a US population of 40,892 men, women, and children who participated in the 2003 National Health Interview Survey. Gaussian mixture models characterised the relationship between migraine, age, and sex. Migraine prevalence was 8.6% (males), 17.5% (females), and 13.2% (overall) and showed a bimodal distribution in both sexes (peaking in the late teens and 20s and around 50 years of age). Rate of change in migraine prevalence for both sexes increased the fastest from age 3 years to the mid-20s. Beyond the age of 10 years, females had a higher prevalence of migraine than males. The prevalence ratio for females versus males was highest during the female reproductive/child-bearing years, consistent with a relationship between menstruation and migraine. After age 42 years, the prevalence ratio was approximately 2-fold higher in women.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available